Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of Clostridioides difficile Infection: A Single-Center Study.
Majd S AlsoubaniJennifer K ChowAngie Mae RoddayDavid KentDavid R SnydmanPublished in: Open forum infectious diseases (2023)
The findings of this study suggest that the use of fidaxomicin for treatment of CDI reduces poor outcomes in patients who are immunocompromised.